The conference serves as a strategic venue for the German biotechnology company to accelerate the adoption of its diagnostic tools. SphingoTec specializes in out-licensing solutions for acute medical conditions, maintaining a portfolio that features Proenkephalin A 119-159 (penKid) for kidney function assessment and bioactive Adrenomedullin 1-52 (bio-ADM) for monitoring endothelial function in sepsis patients. By engaging with industry leaders at ADLM, the company intends to transition its biomarker innovations into broader clinical use across various IVD platforms.
Bergmann emphasized that these interactions are vital for aligning the firm’s technical developments with the practical needs of the diagnostics ecosystem. The company continues to prioritize scaling its commercial presence, utilizing the event to solidify collaborations that support its goal of delivering clinically meaningful diagnostic solutions for critical care environments.
Comments (0)
No comments yet. Be the first!